{"id":"busulfan-bu","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Hepatotoxicity (veno-occlusive disease)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Seizures"},{"rate":null,"effect":"Secondary malignancies"}]},"_chembl":null,"_dailymed":{"setId":"9955aced-ac32-43e6-b39a-c6c023a50dc3","title":"BUSULFAN INJECTION [MYLAN INSTITUTIONAL LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Busulfan covalently binds to DNA through its reactive methanesulfonate groups, creating interstrand and intrastrand cross-links that prevent DNA replication and transcription. This leads to apoptosis of rapidly dividing cells, particularly hematopoietic cells. It is used as a conditioning agent to ablate the bone marrow before stem cell transplantation, allowing engraftment of donor cells.","oneSentence":"Busulfan is an alkylating agent that cross-links DNA, causing strand breaks and cell death, primarily used for myeloablation in hematopoietic stem cell transplantation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:55:27.259Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Conditioning agent for hematopoietic stem cell transplantation in chronic myeloid leukemia"},{"name":"Conditioning agent for hematopoietic stem cell transplantation in other hematologic malignancies and severe aplastic anemia"}]},"trialDetails":[{"nctId":"NCT04990323","phase":"PHASE1, PHASE2","title":"US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies","status":"COMPLETED","sponsor":"ExCellThera inc.","startDate":"2021-12-01","conditions":"High Risk Myeloid Malignancies, Cord Blood Transplant","enrollment":13},{"nctId":"NCT07101588","phase":"PHASE4","title":"Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-01-01","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)","enrollment":200},{"nctId":"NCT06816134","phase":"PHASE2","title":"Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-01-30","conditions":"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Transplantation, Stem Cell","enrollment":48},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT06872333","phase":"PHASE2","title":"Allo HSCT for High Risk Hemoglobinopathies","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-11-19","conditions":"Graft Failure, Sickle Cell Disease, Hemoglobinopathies","enrollment":62},{"nctId":"NCT03579875","phase":"PHASE2","title":"Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2018-11-13","conditions":"Fanconi Anemia, Severe Aplastic Anemia, Myelodysplastic Syndromes","enrollment":48},{"nctId":"NCT01175356","phase":"PHASE1","title":"Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2011-12-21","conditions":"Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma","enrollment":99},{"nctId":"NCT03674411","phase":"PHASE2","title":"Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2019-01-02","conditions":"Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Biphenotypic/Undifferentiated Leukemia","enrollment":22},{"nctId":"NCT01961063","phase":"PHASE1","title":"Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2015-12-31","conditions":"AIDS-related Non-Hodgkin Lymphoma, AIDS-related Plasmablastic Lymphoma, AIDS-related Primary Effusion Lymphoma","enrollment":3},{"nctId":"NCT03016806","phase":"","title":"Umbilical Cord Blood Transplantation From Unrelated Donors","status":"RECRUITING","sponsor":"University of Rochester","startDate":"2015-06","conditions":"Acute Leukemia, Immune Deficiency Disorder, Congenital Hematological Disorder","enrollment":30},{"nctId":"NCT02793544","phase":"PHASE2","title":"HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide","status":"COMPLETED","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2016-12","conditions":"Myelodysplastic Syndrome (MDS), Chronic Lymphocytic Leukemia (CLL), Chemotherapy-sensitive Lymphoma","enrollment":80},{"nctId":"NCT06984536","phase":"PHASE2","title":"Reduced ATG Plus Mini PTCy for GVHD Prophylaxis in Haplo-SCT","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-05-21","conditions":"Myelodysplastic Syndrome, Acute Leukemia","enrollment":40},{"nctId":"NCT05735717","phase":"PHASE2","title":"MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2023-05-11","conditions":"Hematologic Malignancy, Acute Leukemia, Remission","enrollment":70},{"nctId":"NCT07052422","phase":"PHASE2, PHASE3","title":"VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2025-07-15","conditions":"Older Patients, Myeloid Malignancies, Conditioning","enrollment":160},{"nctId":"NCT04221035","phase":"PHASE3","title":"High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2019-11-05","conditions":"High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy","enrollment":800},{"nctId":"NCT06674382","phase":"NA","title":"Haplo-HSCT for Myelofibrosis","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-01-01","conditions":"Myelofibrosis","enrollment":39},{"nctId":"NCT06125483","phase":"NA","title":"TBI/Flu/Bu/Mel Combined With Secondary UCBT in Patients With Hematological Malignancies Who Relapsed After Allo-HSCT","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-11-01","conditions":"Hematopoietic Malignancy, Relapse/Recurrence, Hematopoietic Stem Cell Transplantation","enrollment":38},{"nctId":"NCT04547049","phase":"PHASE3","title":"A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2020-09-01","conditions":"Leukemia","enrollment":176},{"nctId":"NCT00638898","phase":"PHASE1","title":"Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2007-02-26","conditions":"Solid Tumor, Adult Central Nervous System Germ Cell Tumor, Adult Rhabdomyosarcoma","enrollment":25},{"nctId":"NCT02506959","phase":"PHASE2","title":"Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-09-14","conditions":"Plasma Cell Leukemia, Plasmacytoma, Recurrent Plasma Cell Myeloma","enrollment":83},{"nctId":"NCT06879847","phase":"NA","title":"A Single-arm, Prospective Study of TBI + BUMEL As a Conditioning Regimen for Salvage HSCT in Patients with R/R AML","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-12-01","conditions":"Relapsed or Refractory Acute Myeloid Leukemia","enrollment":40},{"nctId":"NCT06548958","phase":"NA","title":"A Single-Arm, Prospective Study of TBI+BUMEL as Conditioning for SCT2 in Patients With Malignant Hematologic Diseases","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-07-10","conditions":"Malignant Hematological Diseases","enrollment":40},{"nctId":"NCT06809699","phase":"PHASE1","title":"Human Leukocyte Antigen (HLA) Mismatched Related Allogeneic Hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"He Huang","startDate":"2022-08-04","conditions":"Hematologic Diseases","enrollment":29},{"nctId":"NCT06809712","phase":"PHASE1","title":"Human Leukocyte Antigen (HLA) Mismatched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"He Huang","startDate":"2022-08-04","conditions":"Hematologic Disease","enrollment":29},{"nctId":"NCT06758726","phase":"NA","title":"Mitoxantrone Hydrochloride Liposome Combined With BU/Cy Were Used as a Conditioning Regimen for Patients With Intermediate/Adverse Risk or Persistently Positive MRD AML","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-12-31","conditions":"AML","enrollment":20},{"nctId":"NCT06673459","phase":"PHASE3","title":"BuCy Vs. TBICy for Allo-HSCT in T-ALL Patients","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-12-01","conditions":"T-Cell Lymphocytic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Total Body Irradiation","enrollment":430},{"nctId":"NCT06613035","phase":"PHASE3","title":"Twice-per-weekSelinexor, 2 Days Melphalan","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-09-30","conditions":"Acute Myeloid Leukemia","enrollment":126},{"nctId":"NCT06571825","phase":"PHASE4","title":"RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR","status":"RECRUITING","sponsor":"He Huang","startDate":"2024-07-17","conditions":"Acute Myeloid Leukemia","enrollment":118},{"nctId":"NCT04009525","phase":"PHASE4","title":"Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study","status":"COMPLETED","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2019-07-05","conditions":"Thalassemia Major","enrollment":823},{"nctId":"NCT06468267","phase":"PHASE2","title":"RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL.","status":"RECRUITING","sponsor":"Xianmin Song, MD","startDate":"2024-07-15","conditions":"Peripheral T Cell Lymphoma","enrollment":50},{"nctId":"NCT06111612","phase":"","title":"Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2024-01-20","conditions":"Acute Myeloid Leukemia, Myelodysplastic Neoplasm, Chronic Myelomonocytic Leukemia","enrollment":50},{"nctId":"NCT06247917","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of Allogeneic Haematopoietic Stem Cell Transplantation With FBM Conditioning for MDS","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2024-03-03","conditions":"Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome With Excess Blasts-2, Myelodysplastic Syndromes","enrollment":59},{"nctId":"NCT00630565","phase":"PHASE2, PHASE3","title":"Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2006-07-26","conditions":"Leukemia","enrollment":12},{"nctId":"NCT01949129","phase":"PHASE2, PHASE3","title":"Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia","status":"RECRUITING","sponsor":"St. Anna Kinderkrebsforschung","startDate":"2013-04","conditions":"Acute Lymphoblastic Leukaemia","enrollment":1800},{"nctId":"NCT00540995","phase":"PHASE1, PHASE2","title":"Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer","status":"TERMINATED","sponsor":"City of Hope Medical Center","startDate":"2007-06-11","conditions":"Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)","enrollment":25},{"nctId":"NCT06069180","phase":"PHASE4","title":"The Optimization of Conditioning Regimen for HLA Matched HSCT in SAA","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2023-11-15","conditions":"Severe Aplastic Anemia","enrollment":160},{"nctId":"NCT06133556","phase":"PHASE2","title":"Conditioning Regimen Containing Melphalan and Cladribine for Refractory / Relapsed AML","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-11-24","conditions":"Acute Myeloid Leukemia","enrollment":237},{"nctId":"NCT04269811","phase":"PHASE2","title":"Flu-Bu-Mel Conditioning Regimen for Myeloid Disease","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2020-01-15","conditions":"Relapse Rate After Allo-HSCT","enrollment":49},{"nctId":"NCT04897139","phase":"PHASE2","title":"Flu-Bu-Mel Based Conditioning Regimen for Patients With Lymphoid Malignancies Undergoing Allo-HSCT","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2021-01-01","conditions":"Lymphoid Neoplasm","enrollment":23},{"nctId":"NCT02248597","phase":"PHASE2","title":"Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2015-02-25","conditions":"Graft Versus Host Disease, Hematopoietic/Lymphoid Cancer","enrollment":27},{"nctId":"NCT01044745","phase":"PHASE2","title":"Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2009-12-10","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission","enrollment":20},{"nctId":"NCT05929092","phase":"NA","title":"TFBC Combined With UCBT in the Treatment of High-risk Malignant Hematological Diseases","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-06-01","conditions":"Hematopoietic Stem Cell Transplantation, Malignant Hematological Diseases","enrollment":40},{"nctId":"NCT05907486","phase":"PHASE3","title":"The Use of N-acetylcysteine for Thrombotic Events After Allogenic Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-08-01","conditions":"Thrombotic Disorder","enrollment":260},{"nctId":"NCT05814731","phase":"NA","title":"Study on the Efficacy and Safety of MA-BUCY2 Conditioning in High-risk AML Patients Underwent Haplo-HSCT","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2023-04-15","conditions":"Haploidentical Stem Cell Transplantation, Conditioning","enrollment":264},{"nctId":"NCT04067180","phase":"NA","title":"Randomized Clinical Study Assessing Haplo vs. URD in AML","status":"TERMINATED","sponsor":"Karolinska Institutet","startDate":"2019-11-12","conditions":"Acute Myeloid Leukemia","enrollment":18},{"nctId":"NCT05453552","phase":"PHASE2, PHASE3","title":"G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2022-07-01","conditions":"Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning","enrollment":242},{"nctId":"NCT01191957","phase":"PHASE3","title":"Busulfan (BU) Plus Fludarabine Vs Intravenous BU Plus Cyclophosphamide as Conditioning Regimens Prior Allogeneic Hematopoetic Stem Cells Transplant (HSCT) in AML","status":"COMPLETED","sponsor":"Gruppo Italiano Trapianto di Midollo Osseo","startDate":"2008-01","conditions":"Acute Myeloid Leukemia (AML)","enrollment":252},{"nctId":"NCT05739630","phase":"PHASE2, PHASE3","title":"M-PTCy vs BuCy in Haploidentical HSCT for Acute Leukemia","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-01-01","conditions":"Acute Leukemia","enrollment":60},{"nctId":"NCT02743351","phase":"PHASE1, PHASE2","title":"Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies","status":"COMPLETED","sponsor":"Fate Therapeutics","startDate":"2016-12-20","conditions":"Hematologic Malignancies, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia","enrollment":96},{"nctId":"NCT01339910","phase":"PHASE3","title":"Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)","status":"TERMINATED","sponsor":"Medical College of Wisconsin","startDate":"2011-06","conditions":"Leukemia, Myelocytic, Acute","enrollment":272},{"nctId":"NCT01410344","phase":"PHASE2","title":"Allogeneic Transplant in HIV Patients (BMT CTN 0903)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2011-09","conditions":"Leukemia, Lymphoma, HIV","enrollment":20},{"nctId":"NCT05449899","phase":"PHASE2, PHASE3","title":"G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for Secondary Acute Myeloid Leukemia Undergoing Allo-HSCT","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2022-07","conditions":"Secondary Acute Myeloid Leukemia Evolving From MDS, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning","enrollment":232},{"nctId":"NCT05303727","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-08","conditions":"Neuroblastoma","enrollment":64},{"nctId":"NCT02670252","phase":"PHASE3","title":"BuCY vs TBICY Conditioning Regimen for Standard-risk ALL Undergoing Allo-HSCT","status":"COMPLETED","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2016-01","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Total Body Irradiation","enrollment":550},{"nctId":"NCT02744742","phase":"PHASE2, PHASE3","title":"G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT","status":"COMPLETED","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2016-04-18","conditions":"Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning","enrollment":202},{"nctId":"NCT01471444","phase":"PHASE3","title":"Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-11-02","conditions":"Disorder Related to Bone Marrow Transplantation, Leukemia, Transplantation Infection","enrollment":256},{"nctId":"NCT05075681","phase":"PHASE1, PHASE2","title":"Ruxolitinib and Chidamide for Acute T Cell Lymphoblast Leukemia/ Lymphoblastic Lymphoma","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2021-11-01","conditions":"Peripheral Blood Stem Cell Transplantation","enrollment":50},{"nctId":"NCT02120157","phase":"PHASE2","title":"Myeloablative Haploidentical BMT With Post-transplant Cyclophosphamide for Pediatric Patients With Hematologic Malignancies","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2015-07-02","conditions":"Myeloablative Conditioning, HLA-mismatched Bone Marrow Transplantation, Graft Survival","enrollment":35},{"nctId":"NCT05088226","phase":"PHASE2","title":"Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2021-12-01","conditions":"Peripheral Blood Stem Cell Transplantation","enrollment":50},{"nctId":"NCT00350181","phase":"PHASE2","title":"Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT","status":"COMPLETED","sponsor":"Stanford University","startDate":"2006-08","conditions":"Leukemia, Lymphoma, Non-Hodgkin, Hematologic Diseases","enrollment":11},{"nctId":"NCT01814475","phase":"PHASE2","title":"Study to Compare Busulfan-fludarabine With Thiotepa-fludarabine Regimen in Allogeneic Transplantation for Myelofibrosis","status":"COMPLETED","sponsor":"Gruppo Italiano Trapianto di Midollo Osseo","startDate":"2011-07","conditions":"Myelofibrosis","enrollment":62},{"nctId":"NCT03492749","phase":"","title":"Busulfan Concentration in Saliva and Plasma, and Its Relationship With Salivary Changes and Mucositis in the Digestive Tract of Patients Submitted to Hematopoietic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Hospital Israelita Albert Einstein","startDate":"2016-02","conditions":"Bone Marrow Disease","enrollment":80},{"nctId":"NCT02129582","phase":"PHASE1","title":"Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2014-11-05","conditions":"Acute Myeloid Leukemia, Hematologic Malignancies, Acute Lymphocytic Leukemia","enrollment":14},{"nctId":"NCT00536601","phase":"NA","title":"High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2006-06-29","conditions":"Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities","enrollment":174},{"nctId":"NCT04786002","phase":"","title":"Target Busulfan Exposure in Children With HSCT in China","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2020-11-01","conditions":"Hematopoietic Stem Cell Transplantation","enrollment":500},{"nctId":"NCT00176930","phase":"NA","title":"Stem Cell Transplant for Hematological Malignancy","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2001-10","conditions":"Leukemia, Myeloid, Chronic, AML, Leukemia, Lymphocytic, Acute","enrollment":330},{"nctId":"NCT04713956","phase":"PHASE2, PHASE3","title":"G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for RAEB-1,REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2021-01-15","conditions":"Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning","enrollment":242},{"nctId":"NCT03530085","phase":"PHASE2, PHASE3","title":"Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCT","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2018-06-15","conditions":"Acute Myeloid Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning","enrollment":60},{"nctId":"NCT04451200","phase":"PHASE2","title":"Sequential and Personalized PK-guided Busulfan Administration in the Frame of the Conditiong Regimen for Allo-HSCT in Patients With Malignant Hemopathies Ineligible for the Standard Myeloablative Conditioning","status":"NOT_YET_RECRUITING","sponsor":"Institut Paoli-Calmettes","startDate":"2020-11","conditions":"Acute Leukemia, Mielodysplasic Syndrome, Myeloproliferative Neoplasm","enrollment":82},{"nctId":"NCT04582604","phase":"PHASE1, PHASE2","title":"Ruxolitinib and Decitabine for High Risk Hematological Malignancies","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2020-09-01","conditions":"Peripheral Blood Stem Cell Transplantation","enrollment":60},{"nctId":"NCT00941720","phase":"PHASE2","title":"Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2009-06-11","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":71},{"nctId":"NCT00857389","phase":"PHASE2","title":"Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-03-02","conditions":"Stem Cell Transplantation, Leukemia, Lymphoma","enrollment":60},{"nctId":"NCT03793517","phase":"PHASE2, PHASE3","title":"Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2018-09-01","conditions":"Stem Cell Transplant Complications, Leukemia, Myeloid, Acute, Leukemia Relapse","enrollment":55},{"nctId":"NCT03821987","phase":"NA","title":"Risk Stratification Directed Conditioning Regimen for Haploidentical HSCT in SAA","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2018-12-17","conditions":"Aplastic Anemia, Stem Cell Transplant Complications, Engraft Failure","enrollment":55},{"nctId":"NCT02671708","phase":"PHASE2, PHASE3","title":"IDA+BUCY vs BUCY Conditioning Regimen for Intermediate-risk AML Undergoing Auto-HSCT","status":"COMPLETED","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2016-01","conditions":"Autologous Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia, Conditioning","enrollment":153},{"nctId":"NCT00176852","phase":"PHASE2, PHASE3","title":"Stem Cell Transplant for Hemoglobinopathy","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2002-06","conditions":"Sickle Cell Disease, Thalassemia, Severe Congenital Neutropenia","enrollment":22},{"nctId":"NCT03385096","phase":"PHASE2, PHASE3","title":"Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2018-01-02","conditions":"Autologous Hematopoietic Stem Cell Transplantation, Conditioning, Multiple Myeloma","enrollment":122},{"nctId":"NCT02589145","phase":"PHASE1, PHASE2","title":"Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-06-22","conditions":"Lymphoma","enrollment":8},{"nctId":"NCT01707004","phase":"PHASE2","title":"Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2013-05-16","conditions":"Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities","enrollment":20},{"nctId":"NCT04123392","phase":"PHASE2, PHASE3","title":"Decitabine + BUCY vs BUCY Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allo-HSCT","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2019-10","conditions":"TP53, Myeloid Tumors, Conditioning","enrollment":196},{"nctId":"NCT04098653","phase":"PHASE2, PHASE3","title":"Decitabine + BUCY vs BUCY Conditioning Regimen for Myeloid Tumors Undergoing Allo-HSCT","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2019-09","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning, Myeloid Tumors","enrollment":196},{"nctId":"NCT03799224","phase":"PHASE2, PHASE3","title":"Decitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute Leukemia","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2018-12-01","conditions":"Stem Cell Transplant Complications, Relapse Leukemia, Refractory Leukemia","enrollment":55},{"nctId":"NCT02670564","phase":"PHASE4","title":"ALL SCTped FORUM - Pharmacogenomic Study (add-on Study)","status":"RECRUITING","sponsor":"Swiss Pediatric Oncology Group","startDate":"2013-04","conditions":"Acute Lymphoblastic Leukemia","enrollment":1000},{"nctId":"NCT01093586","phase":"PHASE2","title":"Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2007-09","conditions":"Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7)","enrollment":14},{"nctId":"NCT03733327","phase":"PHASE2, PHASE3","title":"BUCYE Conditioning Regimen for PCNSL Undergoing Auto-HSCT","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2018-11","conditions":"Primary Central Nervous System Lymphoma, Autologous Hematopoietic Stem Cell Transplantation, Conditioning","enrollment":20},{"nctId":"NCT01435447","phase":"PHASE2","title":"Fludarabine/Busulfan and Cyclophosphamide Conditioning for Adult Lymphoid Malignancies","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2011-04","conditions":"Lymphoid Malignancies","enrollment":31},{"nctId":"NCT00134017","phase":"PHASE2","title":"Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2004-06","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":142},{"nctId":"NCT03602131","phase":"PHASE2","title":"Chidamide Combined With Clad/Gem/Bu With AutoSCT in High Risk Hodgkin & Non-Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"Sichuan University","startDate":"2019-01-01","conditions":"Hodgkin Lymphoma, Non-hodgkin Lymphoma","enrollment":30},{"nctId":"NCT03596892","phase":"PHASE2, PHASE3","title":"Decitabine+BUCY vs BUCY Conditioning Regimen for MLL+ Acute Leukemia Undergoing Allo-HSCT","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2018-07","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation, Conditions, Mixed-lineage-leukemia (MLL)-Rearranged Acute Leukemia","enrollment":122},{"nctId":"NCT01037764","phase":"PHASE2","title":"Donor-specific Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia (ALL)","status":"TERMINATED","sponsor":"Asan Medical Center","startDate":"2010-01","conditions":"Acute Lymphoid Leukemia","enrollment":100},{"nctId":"NCT03151876","phase":"PHASE2","title":"Chidamide Combined With Clad/Gem/Bu With AutoSCT in R/R Diffuse Large B Cell Lymphoma","status":"UNKNOWN","sponsor":"Sichuan University","startDate":"2017-06-12","conditions":"Lymphoma","enrollment":93},{"nctId":"NCT01883180","phase":"PHASE4","title":"ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis","status":"COMPLETED","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2013-06","conditions":"Hematopoietic Stem Cell Transplantation, Antithymocyte Globulin, Viral Infection","enrollment":412},{"nctId":"NCT01779882","phase":"NA","title":"Cyclophosphamide and Busulfan as Conditioning Regimen Before Allogeneic HSCT","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2013-01","conditions":"Myeloid Leukemia, Precursor Myeloid Neoplasms, Lymphoid Neoplasms","enrollment":72},{"nctId":"NCT00445744","phase":"NA","title":"Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2006-12","conditions":"Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)","enrollment":52},{"nctId":"NCT01565616","phase":"PHASE2","title":"Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease","status":"COMPLETED","sponsor":"Emory University","startDate":"2012-03","conditions":"Sickle Cell Disease","enrollment":22},{"nctId":"NCT03229616","phase":"PHASE2, PHASE3","title":"BUCY+VP-16 vs BUCY Conditioning Regimen for DLBCL Undergoing Auto-HSCT","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2017-07-05","conditions":"Autologous Hematopoietic Stem Cell Transplantation, Diffuse Large B-cell Lymphoma, Conditioning","enrollment":122},{"nctId":"NCT00245037","phase":"PHASE1, PHASE2","title":"Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2005-06","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":147},{"nctId":"NCT00005940","phase":"PHASE2","title":"Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia in First Remission","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"1999-10","conditions":"Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)","enrollment":18},{"nctId":"NCT00003199","phase":"PHASE2","title":"Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"1997-11","conditions":"Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, Inflammatory Breast Cancer","enrollment":50},{"nctId":"NCT03190733","phase":"PHASE4","title":"A Optimal Anti-Thymoglobuline (ATG) Dose Decrease cGVHD But Not Increase Leukemia Relapse for Haplo-HSCT","status":"UNKNOWN","sponsor":"Zhujiang Hospital","startDate":"2017-08-30","conditions":"Chronic Graft-versus-host-disease, Leukemia Relapse","enrollment":192}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":523,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Busulfan (BU)","genericName":"Busulfan (BU)","companyName":"Nanfang Hospital, Southern Medical University","companyId":"nanfang-hospital-southern-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Busulfan is an alkylating agent that cross-links DNA, causing strand breaks and cell death, primarily used for myeloablation in hematopoietic stem cell transplantation. Used for Conditioning agent for hematopoietic stem cell transplantation in chronic myeloid leukemia, Conditioning agent for hematopoietic stem cell transplantation in other hematologic malignancies and severe aplastic anemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}